Breaking News

Absci Opens Door to New Biotechnology Campus

Vancouver, WA headquarters expands company’s ability to accelerate discovery and development of next generation biologic drugs.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Absci Corporation, the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, opened its new campus located in Vancouver, WA, a few miles east of the downtown location that housed the company for the last four years.
 
“Absci has been an incredibly positive force in the Vancouver community since establishing its headquarters here in 2016,” said Washington Governor Jay Inslee. “I have followed Absci’s progress as it expanded within and has now outgrown that initial Vancouver facility. Absci is not only attracting investment and top talent to Washington, it is continuously innovating, creating exciting new possibilities for the future of medicine. I look forward to cutting the ribbon on Absci’s new campus early next month, and to continuing to support the development of our biotechnology ecosystem here in Washington.”
 
The new Absci facility was concepted and constructed in a close collaboration between the company, Portland design firm Bora Architecture & Interiors, and local contractor Bremik Construction. Covering over 85,000 square feet of laboratory, office and meeting spaces, it features regionally sourced, renewable, and natural building materials, custom finishes and a vibrant aesthetic.
 
The scalable laboratory space was designed to maximize flow, increase capacity, and readily reconfigure as needed. In addition to tripling capacity for program execution, the incorporation of in-house tissue culture capabilities, high throughput analytical instrumentation, advanced liquid handling and automation, and a dedicated clean air fermentation facility, in conjunction with a state-of-the-art offsite computational cluster, facilitate the expanded scope of Absci’s research and development activities. Additionally, integrated technologies for high volume data capture across Absci’s workflow generate the input for ongoing training of Absci’s Denovium Engine deep learning AI models for drug discovery and cell line design.
 
“It’s inspiring to come to work each day in this exceptional building,” said Sean McClain, founder and CEO of Absci. “We designed the light-filled space around collaboration and the pursuit of scientific excellence, and we are thrilled with the pride our Unlimiters feel inhabiting this new campus. We strive every day to bring new insights to challenging problems, and this collaborative setting really encourages all of us to step beyond the impossible to create new possibilities for patients.”

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters